HK1146902A1 - Nmda receptor antagonists for neuroprotection - Google Patents
Nmda receptor antagonists for neuroprotectionInfo
- Publication number
- HK1146902A1 HK1146902A1 HK11101017.4A HK11101017A HK1146902A1 HK 1146902 A1 HK1146902 A1 HK 1146902A1 HK 11101017 A HK11101017 A HK 11101017A HK 1146902 A1 HK1146902 A1 HK 1146902A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- alkyl
- bond
- nmda receptor
- nr8c
- nr6r7
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/34—Ethylene-urea
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94727607P | 2007-06-29 | 2007-06-29 | |
US94912007P | 2007-07-11 | 2007-07-11 | |
US98508207P | 2007-11-02 | 2007-11-02 | |
US12710508P | 2008-05-09 | 2008-05-09 | |
PCT/US2008/068843 WO2009006437A1 (en) | 2007-06-29 | 2008-06-30 | Nmda receptor antagonists for neuroprotection |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1146902A1 true HK1146902A1 (en) | 2011-07-22 |
Family
ID=40226514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11101017.4A HK1146902A1 (en) | 2007-06-29 | 2011-01-31 | Nmda receptor antagonists for neuroprotection |
Country Status (16)
Country | Link |
---|---|
US (2) | US8420680B2 (xx) |
EP (1) | EP2170334B1 (xx) |
JP (1) | JP2010532382A (xx) |
KR (1) | KR20100045983A (xx) |
CN (3) | CN101815518B (xx) |
AU (1) | AU2008272964A1 (xx) |
BR (1) | BRPI0813001A2 (xx) |
CA (1) | CA2693032A1 (xx) |
CO (1) | CO6290666A2 (xx) |
EA (1) | EA201070077A1 (xx) |
HK (1) | HK1146902A1 (xx) |
MX (1) | MX2009014216A (xx) |
NZ (1) | NZ582917A (xx) |
SG (1) | SG182964A1 (xx) |
WO (1) | WO2009006437A1 (xx) |
ZA (1) | ZA201001874B (xx) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2142529T3 (da) | 2007-04-27 | 2014-02-10 | Purdue Pharma Lp | Trpv1-antagonister og anvendelser deraf |
SG195568A1 (en) * | 2008-05-09 | 2013-12-30 | Univ Emory | Nmda receptor antagonists for the treatment of neuropsychiatric disorders |
US7964605B2 (en) * | 2008-05-29 | 2011-06-21 | Sk Holdings Co., Ltd. | Phenyl piperazine compounds, pharmaceutical composition comprising the same, and use thereof |
IN2012DN06631A (xx) | 2010-02-16 | 2015-10-23 | Pfizer | |
EP2723732B1 (en) | 2011-06-22 | 2017-01-18 | Purdue Pharma LP | Trpv1 antagonists including dihydroxy substituent and uses thereof |
US8841301B2 (en) | 2011-09-26 | 2014-09-23 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
US8722670B2 (en) | 2011-09-30 | 2014-05-13 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
WO2013169964A1 (en) * | 2012-05-09 | 2013-11-14 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
WO2014210456A1 (en) | 2013-06-28 | 2014-12-31 | Emory University | Pyrazoline dihydroquinolones, pharmaceutical compositions, and uses |
CN106163980A (zh) * | 2013-11-05 | 2016-11-23 | 加利福尼亚大学董事会 | 混合碳纳米管和石墨烯纳米结构体 |
US9340504B2 (en) * | 2013-11-21 | 2016-05-17 | Purdue Pharma L.P. | Pyridine and piperidine derivatives as novel sodium channel blockers |
US9187506B2 (en) | 2014-01-09 | 2015-11-17 | Bristol-Myers Squibb Company | (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
US9221796B2 (en) | 2014-01-09 | 2015-12-29 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
CN105085433B (zh) * | 2014-05-19 | 2019-06-25 | 中国科学院上海药物研究所 | 取代酰胺苯酚类化合物及其制备方法、药物组合物和用途 |
US10537552B2 (en) | 2015-05-05 | 2020-01-21 | Carafe Drug Innovation, Llc | Substituted 5-hydroxyoxindoles and their use as analgesics and fever reducers |
EP3362441B1 (en) | 2015-10-14 | 2020-08-12 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
CA3001894A1 (en) | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
ES2843724T3 (es) | 2015-11-30 | 2021-07-20 | Inst Nat Sante Rech Med | Antagonistas de NMDAR para el tratamiento de la angiogénesis tumoral |
EP3672934A4 (en) * | 2017-08-21 | 2021-05-05 | Plex Pharmaceuticals, Inc. | DOUBLE ACTING FKBP12 AND FKBP52 INHIBITORS |
WO2019157014A1 (en) | 2018-02-06 | 2019-08-15 | Emory University | N-methyl-d-aspartic acid receptor modulators |
WO2019191424A1 (en) | 2018-03-28 | 2019-10-03 | Emory University | Glun2c/d subunit selective antagonists of the n-methyl-d-aspartate receptor |
CN114539129B (zh) * | 2020-11-18 | 2023-06-09 | 上海中医药大学附属龙华医院 | 烯丙胺类双功能化合物及其用途 |
WO2023034589A1 (en) * | 2021-09-02 | 2023-03-09 | Emory University | Glun2b-subunit selective antagonists of the n-methyl-d-aspartate receptors with enhanced potency at acidic ph |
CN113861064B (zh) * | 2021-10-14 | 2024-05-10 | 南京医科大学 | 一类神经保护剂及其药物用途 |
Family Cites Families (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1325876A (en) * | 1969-08-15 | 1973-08-08 | Pfizer Ltd | Piperazine derivatives their preparation and pharmaceutical compositions containing them |
GB1361863A (en) * | 1972-09-25 | 1974-07-30 | Pfizer Ltd | Piperazine derivatives their preparation and pharmaceutical compositions containing them |
US4210753A (en) * | 1976-03-17 | 1980-07-01 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril compounds |
JPS56164186A (en) * | 1980-05-21 | 1981-12-17 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
JPS579769A (en) * | 1980-06-23 | 1982-01-19 | Otsuka Pharmaceut Co Ltd | 2-benzimidazolinone derivative |
DE3023369A1 (de) * | 1980-06-23 | 1982-01-14 | Boehringer Mannheim Gmbh, 6800 Mannheim | Aryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
CN85108214A (zh) * | 1984-11-22 | 1986-08-20 | 赫彻斯特股份公司 | 新的取代的苯基哌嗪衍生物及其药物的制造方法 |
GB8610668D0 (en) * | 1986-05-01 | 1986-06-04 | Pfizer Ltd | Anti-arrhythmia agents |
EG18188A (en) | 1986-05-01 | 1992-09-30 | Pfizer Ltd | Process for preparation anti-arhythmia agents |
US4906779A (en) | 1986-07-10 | 1990-03-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
US5190976A (en) | 1986-07-10 | 1993-03-02 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And University Of Oregon | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
US5093525A (en) | 1986-07-10 | 1992-03-03 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
US5179085A (en) | 1989-03-15 | 1993-01-12 | Warner-Lambert Company | N-substituted α-amino acids and derivatives thereof having pharmaceutical activity |
US4957909A (en) | 1989-05-04 | 1990-09-18 | American Home Products Corporation | Benzobicycloalkane derivatives as anticonvulsant neuroprotective agents |
US4924008A (en) | 1989-05-04 | 1990-05-08 | American Home Products Corporation | Benzobicycloalkane derivatives as anticonvulsant neuroprotective agents |
US4994467A (en) | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
US5326756A (en) | 1989-09-19 | 1994-07-05 | Merrell Dow Pharmaceuticals Inc. | R-4-oxo-5 phosphononorvaline used as NMDA antagonists |
US5095009A (en) | 1990-04-11 | 1992-03-10 | Merrell Dow Pharmaceuticals Inc. | NMDA antagonists |
US5500419A (en) | 1989-09-19 | 1996-03-19 | Merrell Dow Pharmaceuticals Inc. | NMDA antagonists |
US5034400A (en) | 1989-10-20 | 1991-07-23 | Olney John W | Method for preventing neurotoxic side effects of NMDA antagonists |
US5474990A (en) | 1989-10-20 | 1995-12-12 | Olney; John W. | Barbiturates as safening agents in conjunction with NMDA antagonists |
US5629307A (en) | 1989-10-20 | 1997-05-13 | Olney; John W. | Use of ibogaine in reducing excitotoxic brain damage |
EP0424179A3 (en) | 1989-10-20 | 1991-12-27 | John William Olney | Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration |
US5767130A (en) | 1989-10-20 | 1998-06-16 | Olney; John W. | Use of kainic acid antagonists to prevent toxic side effects of NMDA antagonists |
US5132313A (en) | 1989-10-26 | 1992-07-21 | University Of Pittsburgh | Non-competitive NMDA receptor antagonists and methods for their use |
US5013540A (en) | 1989-11-30 | 1991-05-07 | Board Of Regents, The University Of Texas System | Using NMDA receptor antagonists to reduce damage due to laser treatment |
US4994459A (en) * | 1989-12-11 | 1991-02-19 | American Home Products Corporation | Aryloxypropane substituted piperazine derivatives with antiarrhythmic and antifibrillatory activity |
US5039528A (en) | 1989-12-11 | 1991-08-13 | Olney John W | EAA antagonists as anti-emetic drugs |
US5336689A (en) | 1990-03-02 | 1994-08-09 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists |
US5262568A (en) | 1990-03-02 | 1993-11-16 | State Of Oregon | Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists |
WO1991012797A1 (en) | 1990-03-02 | 1991-09-05 | STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALF SCIENCES UNIVERSITY | Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists |
GB9005318D0 (en) * | 1990-03-09 | 1990-05-02 | Isis Innovation | Antiarrhythmic agents |
US5194430A (en) | 1990-05-17 | 1993-03-16 | Merrell Dow Pharmaceuticals Inc. | Heterocyclic-nmda antagonists |
WO1992001670A1 (en) | 1990-07-16 | 1992-02-06 | Merrell Dow Pharmaceuticals Inc. | Excitatory amino acid antagonists |
EP0553278B1 (en) | 1990-10-15 | 1997-06-04 | Astra Aktiebolag | 2-phenyl-and 2-thienyl-(2)-piperidine derivatives having neuroprotective properties |
US5189054A (en) | 1990-11-02 | 1993-02-23 | Merrell Dow Pharmaceuticals Inc. | 3-amidoindolyl derivatives and pharmaceutical compositions thereof |
US5118675A (en) | 1991-02-15 | 1992-06-02 | American Home Products Corporation | Quinoxaline phosphono-amino acids |
US5606063A (en) | 1991-02-27 | 1997-02-25 | Merrell Pharmaceuticals Inc. | NMDA antagonists |
US5594007A (en) | 1991-04-18 | 1997-01-14 | Pfizer Inc. | Method for treating spinal cord trauma with phenolic 2-piperidino-1-alkanols |
DE4123106A1 (de) | 1991-07-09 | 1993-01-14 | Schering Ag | Arzneimittel zur behandlung von entzugssymptomen |
US5124319A (en) | 1991-10-11 | 1992-06-23 | American Home Products Corporation | Benzimidazole phosphono-amino acids |
US5710168A (en) | 1991-10-23 | 1998-01-20 | Pfizer Inc. | 2-piperidino-1-alkanol derivatives as neuroprotective agents |
US5318985A (en) | 1991-12-20 | 1994-06-07 | Merrell Dow Pharmaceuticals Inc. | Potentiation of NMDA antagonists |
US5441963A (en) | 1991-12-20 | 1995-08-15 | Merrell Dow Pharmaceuticals | Potentiation of NMDA antagonists |
DE4222826A1 (de) | 1992-07-09 | 1994-01-13 | Schering Ag | Arzneimittel zur Verhinderung der Toleranzentwicklung während der Behandlung mit Benzodiazepin-Rezeptor-Bindenen Wirkstoffen |
US5192751A (en) | 1992-07-24 | 1993-03-09 | Eli Lilly And Company | Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence |
US5498610A (en) | 1992-11-06 | 1996-03-12 | Pfizer Inc. | Neuroprotective indolone and related derivatives |
CA2111138A1 (en) | 1993-01-15 | 1994-07-16 | Thierry Godel | Octahydrophenanthrene derivatives |
US5321012A (en) | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
US5834479A (en) | 1993-03-05 | 1998-11-10 | Mayer; David J. | Method and composition for alleviating pain |
CA2115792C (en) | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
US5519048A (en) | 1993-05-27 | 1996-05-21 | Merrell Pharmaceuticals Inc. | 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof |
FR2707643B1 (fr) | 1993-07-16 | 1995-08-11 | Rhone Poulenc Rorer Sa | Dérivés d'imidazo[1,2-a]pyrazine-4-one, leur préparation et les médicaments les contenant. |
US5395822A (en) | 1993-09-20 | 1995-03-07 | Izumi; Yukitoshi | Use of pyruvate to prevent neuronal degeneration associated with ischemia |
IS4233A (is) | 1993-12-22 | 1995-06-23 | Astra Aktiebolag | Misleit hringtengd efnasambönd |
US5587384A (en) | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
FR2717805B1 (fr) | 1994-03-28 | 1996-05-10 | Rhone Poulenc Rorer Sa | Dérivés de 5H-indeno[1,2-b]pyrazine-2,3-dione, leur préparation et les médicaments les contenant . |
EP0685466A1 (de) | 1994-06-02 | 1995-12-06 | Ciba-Geigy Ag | 3-Heteroaliphatyl- und 3-Hetero-(aryl)aliphatyl-2(1H)-chinolonderivate |
DE4422517A1 (de) * | 1994-06-28 | 1996-01-04 | Dresden Arzneimittel | Neue (2-(3,4-Dimethoxy-phenyl)-ethyl)-(2-phenoxy-ethyl)-amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
JP3904599B2 (ja) | 1994-08-04 | 2007-04-11 | シー・アンド・シー・リサーチ・ラブズ | 新規なアミン誘導体、その製造方法及び抗不整脈剤としての用途 |
KR960007560A (ko) * | 1994-08-16 | 1996-03-22 | 김정규 | 신규한 아민 유도체, 그의 제조방법 및 항부정맥제로서의 용도 |
GB9418443D0 (en) | 1994-09-13 | 1994-11-02 | Pfizer Ltd | Therapeutic agents |
US6096743A (en) | 1994-09-27 | 2000-08-01 | Yamanouchi Pharmaceuticals Co., Ltd. | 1,2,3,4-tetrahydroquinoxalinedione derivative |
US5563157B1 (en) | 1994-10-31 | 1999-02-02 | Hoecst Marion Roussel Inc | Heterocycle substituted propenoic acid derivatives and pharmaceutical compositions thereof |
FR2726275B1 (fr) | 1994-11-02 | 1996-12-06 | Rhone Poulenc Rorer Sa | Spiro heterocycle-imidazo(1,2-a)indeno(1,2-e)pyrazine)-4'- ones, leur preparation et les medicaments les contenants |
JPH08143557A (ja) * | 1994-11-24 | 1996-06-04 | Toyobo Co Ltd | 新規なフェニルピペラジン誘導体、その塩及びその溶媒和物 |
US5605911A (en) | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
WO1996037226A2 (en) | 1995-05-26 | 1996-11-28 | Pfizer Inc. | Combinations for the treatment of parkinsonism containing selective nmda antagonists |
US5768130A (en) * | 1995-05-15 | 1998-06-16 | Lsi Logic Corporation | Method of calculating macrocell power and delay values |
US5888996A (en) | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
JP4313435B2 (ja) | 1995-07-24 | 2009-08-12 | トラスティーズ オブ ボストン ユニバーシティー | プレグネノロンサルフェート誘導体によるnmdaレセプター活性の抑制 |
US5840731A (en) | 1995-08-02 | 1998-11-24 | Virginia Commonwealth University | Pain-alleviating drug composition and method for alleviating pain |
MY132385A (en) | 1995-08-31 | 2007-10-31 | Novartis Ag | 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives |
AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
TW427978B (en) | 1996-02-03 | 2001-04-01 | Hoffmann La Roche | Tetrahydroisoquinoline derivatives |
WO1997032581A1 (en) | 1996-03-08 | 1997-09-12 | F. Hoffmann-La Roche Ag | Use of 4-phenyl-3,6-dihydro-2h-pyridyl derivatives as nmda receptor subtype blockers |
US6025369A (en) | 1996-05-03 | 2000-02-15 | The Board Of Regents Of The University Nebraska | N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis |
TW498067B (en) | 1996-07-19 | 2002-08-11 | Hoffmann La Roche | 4-hydroxy-piperidine derivatives |
AU4078897A (en) | 1996-08-23 | 1998-03-06 | Algos Pharmaceutical Corporation | Anticonvulsant containing composition for treating neuropathic pain |
US5902815A (en) | 1996-09-03 | 1999-05-11 | Washington University | Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction |
US5958919A (en) | 1996-09-20 | 1999-09-28 | Washington University | Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration |
US5919826A (en) | 1996-10-24 | 1999-07-06 | Algos Pharmaceutical Corporation | Method of alleviating pain |
EP0972766A4 (en) * | 1997-01-30 | 2000-05-03 | Senju Pharma Co | HYDROQUINONE DERIVATIVES |
EP0869122B1 (en) | 1997-03-31 | 2002-12-04 | Korea Research Institute Of Chemical Technology | Quinolinic sulfide derivatives acting as NMDA receptor antagonists and process for preparation thereof |
US5866585A (en) | 1997-05-22 | 1999-02-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia using NMDA receptor antagonists |
US6057373A (en) | 1997-05-22 | 2000-05-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists |
DK1009732T3 (da) | 1997-06-30 | 2003-09-22 | Merz Pharma Gmbh & Co Kgaa | 1-Amino-alkylcyclohexan NMDA receptor antagonister |
US6071966A (en) | 1997-06-30 | 2000-06-06 | Merz + Co. Gmbh & Co. | 1-amino-alkylcyclohexane NMDA receptor antagonists |
US5783700A (en) | 1997-07-03 | 1998-07-21 | Nichols; Alfred C. | Quinolic acid derivatives |
IL125658A0 (en) * | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
HUP0004900A3 (en) | 1997-10-24 | 2002-03-28 | Warner Lambert Co | Pharmaceutical compositions for treating disease-related or drug-induced dyskinesias containing piperidine derivatives as nmda receptor antagonist as active ingredient |
US6177434B1 (en) | 1997-12-16 | 2001-01-23 | The United States Of America As Represented By The Secretary Of The Navy | Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms |
US6294583B1 (en) | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
US6242456B1 (en) | 1998-03-09 | 2001-06-05 | Trustees Of Tufts College | Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors |
US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
US6197820B1 (en) | 1998-04-06 | 2001-03-06 | Uab Research Foundation | Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions |
US6054451A (en) | 1998-04-21 | 2000-04-25 | Algos Pharmaceutical Corporation | Analgesic composition and method for alleviating pain |
PE20000728A1 (es) | 1998-06-26 | 2000-08-21 | Cocensys Inc | Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda |
DE69931316D1 (de) | 1998-08-18 | 2006-06-22 | Hoffmann La Roche | Verwendung von Aryl-Cyclohexylamine Derivaten zur Herstellung von NMDA-Rezeptorblockern |
US6200990B1 (en) | 1998-12-21 | 2001-03-13 | Alcon Laboratories, Inc. | Neuroprotective agents having antioxidant and NMDA antagonist activity |
ATE250610T1 (de) | 1999-06-29 | 2003-10-15 | Neurosearch As | Kaliumkanal-blockierende mittel |
ATE257827T1 (de) | 1999-07-21 | 2004-01-15 | Hoffmann La Roche | Triazolderivate |
GB9917822D0 (en) | 1999-07-29 | 1999-09-29 | Imperial College | Nmda antagonist |
US6339093B1 (en) | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
WO2002028814A2 (en) * | 2000-10-06 | 2002-04-11 | Regents Of The University Of California | Nmda receptor channel blocker with neuroprotective activity |
EP1436258A4 (en) * | 2001-03-08 | 2005-03-23 | Univ Emory | ANTAGONISTS OF THE NMDA RECEPTOR DEPENDENT OF PH |
DE10248925A1 (de) * | 2002-10-15 | 2004-04-29 | Proteosys Ag | Neue Verbindungen mit dopaminerger und/oder serotoninerger Aktivität |
MXPA05012325A (es) * | 2003-05-16 | 2006-01-30 | Pfizer Prod Inc | Procedimiento para potenciar la cognicion usando zipirasidona. |
HUP0401526A2 (en) * | 2004-07-29 | 2006-04-28 | Richter Gedeon Vegyeszet | Aryloxy acetic acid amide derivatives, pharmaceutical compositions comprising thereof, methods for their preparation and their use |
CA2578217A1 (en) * | 2004-08-23 | 2006-03-02 | Emory University | Improved selection of ph-dependent compounds for in vivo therapy |
ES2417488T3 (es) * | 2004-12-02 | 2013-08-08 | Abbott Gmbh & Co. Kg | Compuestos de triazol adecuados para tratar trastornos que responden a la modulación del receptor de dopamina D3 |
ES2435790T3 (es) * | 2004-12-03 | 2013-12-23 | Intervet International B.V. | Piperazinas sustituidas como antagonistas de CB1 |
AR055203A1 (es) * | 2005-08-31 | 2007-08-08 | Otsuka Pharma Co Ltd | Derivados de benzotiofeno con propiedades antipsicoticas |
GB0521320D0 (en) * | 2005-10-20 | 2005-11-30 | Univ Reading The | Beta adrenergic receptor pharmacophore |
WO2007099828A1 (ja) * | 2006-02-23 | 2007-09-07 | Shionogi & Co., Ltd. | 環式基で置換された含窒素複素環誘導体 |
WO2012082735A1 (en) | 2010-12-13 | 2012-06-21 | Nanostim, Inc. | Delivery catheter systems and methods |
-
2008
- 2008-06-30 EP EP08772277.3A patent/EP2170334B1/en active Active
- 2008-06-30 BR BRPI0813001A patent/BRPI0813001A2/pt not_active IP Right Cessation
- 2008-06-30 US US12/165,308 patent/US8420680B2/en active Active
- 2008-06-30 WO PCT/US2008/068843 patent/WO2009006437A1/en active Application Filing
- 2008-06-30 CA CA 2693032 patent/CA2693032A1/en not_active Abandoned
- 2008-06-30 SG SG2012047924A patent/SG182964A1/en unknown
- 2008-06-30 CN CN2008801040780A patent/CN101815518B/zh not_active Expired - Fee Related
- 2008-06-30 MX MX2009014216A patent/MX2009014216A/es active IP Right Grant
- 2008-06-30 CN CN201210492035.2A patent/CN103497114A/zh active Pending
- 2008-06-30 NZ NZ582917A patent/NZ582917A/xx not_active IP Right Cessation
- 2008-06-30 CN CN2012104908670A patent/CN103058957A/zh active Pending
- 2008-06-30 JP JP2010515231A patent/JP2010532382A/ja active Pending
- 2008-06-30 EA EA201070077A patent/EA201070077A1/ru unknown
- 2008-06-30 AU AU2008272964A patent/AU2008272964A1/en not_active Abandoned
- 2008-06-30 KR KR1020107002042A patent/KR20100045983A/ko not_active Application Discontinuation
-
2010
- 2010-01-28 CO CO10008723A patent/CO6290666A2/es active IP Right Grant
- 2010-03-16 ZA ZA2010/01874A patent/ZA201001874B/en unknown
-
2011
- 2011-01-31 HK HK11101017.4A patent/HK1146902A1/xx not_active IP Right Cessation
-
2013
- 2013-04-15 US US13/862,647 patent/US9079852B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20100045983A (ko) | 2010-05-04 |
EP2170334B1 (en) | 2021-03-17 |
CN101815518A (zh) | 2010-08-25 |
EP2170334A1 (en) | 2010-04-07 |
BRPI0813001A2 (pt) | 2019-09-24 |
NZ582917A (en) | 2013-01-25 |
US8420680B2 (en) | 2013-04-16 |
EA201070077A1 (ru) | 2010-08-30 |
ZA201001874B (en) | 2010-11-24 |
JP2010532382A (ja) | 2010-10-07 |
CA2693032A1 (en) | 2009-01-08 |
CN103497114A (zh) | 2014-01-08 |
US20140031363A1 (en) | 2014-01-30 |
SG182964A1 (en) | 2012-08-30 |
CO6290666A2 (es) | 2011-06-20 |
CN101815518B (zh) | 2013-01-09 |
CN103058957A (zh) | 2013-04-24 |
WO2009006437A1 (en) | 2009-01-08 |
AU2008272964A1 (en) | 2009-01-08 |
MX2009014216A (es) | 2010-07-05 |
US9079852B2 (en) | 2015-07-14 |
US20090253710A1 (en) | 2009-10-08 |
EP2170334A4 (en) | 2010-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1146902A1 (en) | Nmda receptor antagonists for neuroprotection | |
MX347706B (es) | Derivados de triazol y su uso para trastornos neurologicos. | |
TNSN07164A1 (en) | Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists | |
UA101352C2 (xx) | Конденсоване похідне амінодигідротіазину$конденсированная производная аминодигидротиазина | |
IL176247A0 (en) | Cyclopropane compounds and pharmaceutical use thereof | |
WO2007084914A3 (en) | Phenoxy-substituted pyrimidines as adenosine receptor antagonists | |
TW200728307A (en) | Novel spirochromanone derivatives | |
JO3360B1 (ar) | الشكل البلوري الجديد 3 للأغوميلاتين وعملية تحضيره والمكونات الصيدلانية التي تحتويه | |
MY142652A (en) | Quinuclidine derivatives binding to muscarinic m3 receptors | |
HUP0101281A2 (hu) | Glicin transzport inhibitor hatású difenil-piperidin-butánamid-származékok, eljárás előállításukra, alkalmazásuk gyógyszerkészítmények előállítására és a vegyületeket tartalmazó gyógyszerkészítmények | |
WO2006113509A3 (en) | Quinobenzoxazine analogs and methods of using thereof | |
MX343788B (es) | Derivados de heteroarilo como moduladores de nachr alfa 7. | |
NZ599254A (en) | Novel vanilloid receptor ligands and the use thereof for the production of pharmaceuticals | |
DE602005022284D1 (de) | Substituierte benzimidazole und deren verwendung zur induktion von apoptose | |
MX2007003922A (es) | Nuevas propenonas ciclicas y aciclicas para tratar trastornos del sistema nervioso central. | |
GEP20115216B (en) | New phenanthridine derivatives as bradykinin antagonists | |
BRPI0517734A (pt) | derivados de 1-[(6,7-alcoxiquinoxalinil substituìdo) aminocarbonil]-4- (hetero) arilpiperazina | |
WO2004111008A3 (en) | Use of a compound of formula i for making a pharmaceutical composition | |
MXPA05012679A (es) | Nuevos derivados de imidazoles, su preparacion y su uso como medicamento. | |
MX2012006955A (es) | Compuestos para el tratamiento de trastornos neurologicos. | |
EP1698618A4 (en) | BENZAMIDE DERIVATIVE | |
SG146627A1 (en) | Imidazole derivatives | |
MX2009010729A (es) | Derivados de dihidro-benzo[b] [1,4]diazepin-2-ona-sulfonamida. | |
HUE029687T2 (en) | New effective HDAC inhibitor thio derivatives and their use as medicaments | |
GEP20125574B (en) | Fused pyrimidine derivatives as trpv3 modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20170630 |